Rafferty Asset Management LLC Decreases Position in Hologic, Inc. $HOLX

Key Points

• Rafferty Asset Management LLC reduced its stake in Hologic, Inc. by 21.1% in the first quarter, leaving it with 20,777 shares valued at approximately $1.28 million.
• Hologic reported earnings of $1.08 per share for the last quarter, exceeding expectations of $1.05, with total revenue reaching $1.02 billion.
• Analysts have recently issued mixed ratings for Hologic, with one firm upgrading it to "outperform" and a range of price targets increasing to a high of $87.00.

Rafferty Asset Management LLC lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 21.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,777 shares of the medical equipment provider's stock after selling 5,570 shares during the period. Rafferty Asset Management LLC's holdings in Hologic were worth $1,283,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in HOLX. Victory Capital Management Inc. increased its position in shares of Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after acquiring an additional 1,692,177 shares during the period. Nuance Investments LLC increased its position in shares of Hologic by 623.7% in the 1st quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock valued at $66,794,000 after acquiring an additional 931,920 shares during the period. Redwood Wealth Management Group LLC acquired a new position in shares of Hologic in the 1st quarter valued at $3,534,000. Invesco Ltd. increased its position in shares of Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after acquiring an additional 764,573 shares during the period. Finally, Nuveen LLC acquired a new position in shares of Hologic in the 1st quarter valued at $30,317,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

Shares of HOLX stock traded up $0.37 during mid-day trading on Friday, hitting $66.76. 1,270,243 shares of the stock were exchanged, compared to its average volume of 1,601,091. The firm has a fifty day moving average of $66.34 and a 200 day moving average of $62.60. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The company has a market cap of $14.85 billion, a PE ratio of 27.70, a price-to-earnings-growth ratio of 2.42 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the company posted $1.06 EPS. The company's revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several research reports. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and upped their target price for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. UBS Group upped their target price on Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. Morgan Stanley increased their price target on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Finally, Mizuho set a $75.00 price target on Hologic in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.